LabCompass

Allison Yan

Medicine · The Ohio State University

OpenAlex ORCID
Mid career · publishing since 2014Rising activity
Drug-Induced Adverse ReactionsAutoimmune Bullous Skin DiseasesAcne and Rosacea Treatments and EffectsHidradenitis Suppurativa and TreatmentsImmune Cell Function and Interaction

Publications

39

Citations

118

Est. group size

~4

Recurring co-author estimate

Active years

13

Publishing since 2014

Research summary
AI-generated

Allison Yan's work focuses on dermatology, particularly on how skin conditions like acne, cellulitis, alopecia areata, and drug-induced skin reactions affect patients' quality of life, and on improving tools used to measure patient-reported outcomes in these conditions. Additional work examines access barriers to treatment, dietary and cost factors in skin disease management, and clinical decision-making tools for common skin conditions.

Patient-reported outcomes in skin diseaseAcne and its managementQuality of life in dermatologic conditionsAccess to care and health disparities in dermatologyDrug-induced skin reactions

Publication output was minimal before 2022 but has grown substantially since, peaking in 2024-2025, indicating a recent increase in research activity.

Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026

Publication cadence
Publications per year over the last 10 years — averaging 7.2/year recently
17182019: 1 publication1920212022: 3 publications222023: 5 publications232024: 14 publications14242025: 13 publications252026: 1 publication26
Recent publications
Publishes in
  • Journal of the American Academy of Dermatology×10
  • Archives of Dermatological Research×7
  • Journal of Investigative Dermatology×4
  • bioRxiv (Cold Spring Harbor Laboratory)×2
  • Journal of Clinical Investigation×1
Similar researchers
By research-topic overlap

This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.

Last updated Jul 19, 2026.

Claim or correct this profile